Aerobic Exercise for Cognitive Functioning in Patients With Substance Use Disorder
NCT05324085, Not applicable, Completed, St. Olavs Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Aerobic Exercise for Cognitive Functioning in Patients With Substance Use Disorder | ClinicalTrials.gov |
| NCT number | NCT05324085 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 84 participants, actual | ClinicalTrials.gov |
| Lead sponsor | St. Olavs Hospital | ClinicalTrials.gov |
| Conditions | Substance Abuse, Cognitive Dysfunction | ClinicalTrials.gov |
| Interventions | High-intensity interval training, Treatment as usual | ClinicalTrials.gov |
| First posted | 2022-04-12 | ClinicalTrials.gov |
| Last updated | 2025-06-10 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in executive function (EF) | 8 weeks | Change in executive function assessed with Behavior Rating Inventory of ExecutiveFunction, Adult (BRIEF-A). BRIEF-A is a 75-item standardized questionnaire appraising EFs in real-life situations. It incorporates self-reported cognitive characteristics and collects subjective information about the ability to maintain appropriate control of emotional responses and behavior. | ClinicalTrials.gov |
| Secondary | Change in Montreal Cognitive Assessment (MoCA) score | 8 weeks | MoCA is a brief neuropsychological assessment to evaluate cognitive function in various domains (i.e. visuospatial/executive abilities, naming, memory, attention, language, abstraction, and orientation). This assessment takes about 10 minutes to perform. Maximum score is 30, but scores from 26 and above is considered normal. | ClinicalTrials.gov |
| Secondary | Change in Stroop test score | 8 weeks | Stroop is a widely used and validated test evaluate attention and impulse control. This particular test allow 90 seconds to solve as many problems as possible. Each correct answer provides one point, while incorrect answers are subtracted from the total score. | ClinicalTrials.gov |
| Secondary | Change in Digit Span test performance | 8 weeks | The Digit Span test is an assessment of working memory, using rows of numbers that should be memorized. Each correct answer provides one point with the following sequence being one digit longer than the previous. The test has no limit on time or upper score, but only allows three mistakes before ending. | ClinicalTrials.gov |
| Secondary | Altered serum concentration of Brain Derived Neurotrophic Factor (BDNF) | 8 weeks | BDNF is a biochemical marker of neurocognitive/neuroprotective mechanisms that can be measured in human serum | ClinicalTrials.gov |
| Secondary | Altered serum concentration of Klotho | 8 weeks | Klotho is a biochemical marker of neurocognitive/neuroprotective mechanisms that can be measured in human serum | ClinicalTrials.gov |
| Secondary | Altered serum concentration of glycosylphosphatidylinositol-specific phospholipase D1 (Gpld1) | 8 weeks | Gpld1 is a biochemical marker of neurocognitive/neuroprotective mechanisms that can be measured in human serum | ClinicalTrials.gov |
| Secondary | Altered serum concentration of interleukin 6 (IL6) | 8 weeks | IL6 is a muscle-secreted protein known to affect neurocognitive/neuroprotective mechanisms | ClinicalTrials.gov |
| Secondary | Change in maximal cardiorespiratory fitness | 8 weeks | Maximal cardiorespiratory fitness will be measured as oxygen uptake by cardiopulmonary exercise testing on a treadmill, by inclined walking or running on a treadmill | ClinicalTrials.gov |
| Secondary | Change in mental distress | 8 weeks | Alterations in mental distress will be assessed using the validated brief questionnaire Symptom Checklist-10 (SCL-10) | ClinicalTrials.gov |
| Secondary | Change in substance use | 8 weeks | Change in substance use will be assessed using a simple self-report questionnaire | ClinicalTrials.gov |
| Secondary | Change in substance craving | 8 weeks | Change in substance use will be assessed using a simple Visual Analogue Scale ranging from 0 (no craving) to 10 (severe craving) | ClinicalTrials.gov |
| Secondary | Change in quality of life | 8 weeks | Quality of life will be assessed with a brief version of the World Health Organization Quality of Life assessment | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 36570498 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)